Frontlight ResearchEarly access
Active, not recruitingNo phase
ADH1 and ADH2 Disease Monitoring Study (DMS)
Key facts
- Who runs it
- Calcilytix Therapeutics, Inc., a BridgeBio company
- Where
- Aurora, Boston, Cincinnati, Columbus, Greenville, Indianapolis, Jacksonville, Oakland, and Rochester, United StatesSee the 9 sitesAlso in 12 other countries, 18 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 95 people enrolled
- Started
- 20 Jan 2022
- Expected to end
- Dec 2028
- Type of study
- Observational
- Record updated
- 30 April 2026
Who can take part
- Age
- Up to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Have a documented activating variant or variant of uncertain significance of the CASR gene causative of ADH1 or documented activating variant or variant of uncertain significance of the GNA11 gene causative of ADH2 associated with a clinical syndrome of hypoparathyroidism prior to enrollment; Note: Acceptable documentation includes CASR or GNA11 genetic analysis report. If no prior documented CASR or GNA11 gene variant or variant of uncertain significance, potential participants can undergo CASR and GNA11 gene variant analysis at Screening
- Be willing and able to provide informed consent or assent after the nature of the study and its details have been explained, and prior to any research-related procedures
- Be willing and able to provide access to prior medical records including imaging, biochemical, and diagnostic and medical history data, if available
- Be willing and able to comply with the study visit schedule and study procedures
Who cannot take part
- Have serious medical or psychiatric comorbidity that, in the opinion of the Investigator, would present a concern for participant safety or compromise the ability to provide consent or assent, or comply with the study visit schedule and study procedures
- Enrollment in an interventional clinical study at the time of DMS Screening visit; Note: Other protocol defined Inclusion/Exclusion criteria may apply
Where in United States
Also in 12 other countries, 18 sites
- Children's Hospital ColoradoAurora, United States
- Boston Children's HospitalBoston, United States
- Cincinnati Children's Hospital Medical CenterCincinnati, United States
- Ohio State University Medical Center (OSUMC)Columbus, United States
- Physician's East EndocrinologyGreenville, United States
- Indiana University (IU) School of Medicine - University HospitalIndianapolis, United States
- Nemours Children's ClinicJacksonville, United States
- University of California, San Francisco (UCSF) - Benioff Children's Hospital - OaklandOakland, United States
- Mayo ClinicRochester, United States
About the trial
What the trial wants to find out
A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospective (over time into the future) data collection.
The group in the trial
- ADH 1/2 DMS
Participants with ADH1 or ADH2. No investigational product will be administered to participants in this study. Participants will only receive standard of care (SoC) treatment as directed by the participants' treating physicians.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Autosomal Dominant Hypocalcemia Types 1 And 2 (ADH1/2) Disease Monitoring Study (DMS)
- Record updated
- 30 April 2026